Literature DB >> 21469113

Cot/tpl2 activity is required for TLR-induced activation of the Akt p70 S6k pathway in macrophages: Implications for NO synthase 2 expression.

Marta López-Peláez1, Irene Soria-Castro, Lisardo Boscá, Margarita Fernández, Susana Alemany.   

Abstract

LPS stimulation activates IKK and different MAP kinase pathways, as well as the PI3K-Akt-mTOR-p70 S6k pathway, a negative regulator of these MyD88-dependent intracellular signals. Here, we show that Cot/tpl2, a MAP3K responsible for the activation of the MKK1-Erk1/2, controls P-Ser473 Akt and P-Thr389 p70 S6k phosphorylation in LPS-stimulated macrophages. Analysis of the intracellular signalling in Cot/tpl2 KO macrophages versus WT macrophages reveals lower IκBα recovery and higher phosphorylation of JNK and p38α after 1 h of LPS stimulation. Moreover, Cot/tpl2 deficiency increases LPS-induced NO synthase 2 (NOS2) expression in macrophages. Inhibition of the PI3K pathway abolishes the differences in IκBα and NOS2 expression between Cot/tpl2 KO and WT macrophages following LPS administration. Furthermore, in zymosan- and polyI:C-stimulated macrophages, Cot/tpl2 mediates P-Ser473 Akt phosphorylation, increases IκBα levels and decreases NOS2 expression. In conclusion, these data reveal a novel role for the Cot/tpl2 pathway in mediating TLR activation of the Akt-mTOR-p70 S6k pathway, allowing Cot/tpl2 to fine-control the activation state of other signalling pathways.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21469113     DOI: 10.1002/eji.201041101

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  36 in total

1.  Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma.

Authors:  Jeffrey Lee Jensen; Alexander Rakhmilevich; Erika Heninger; Aimee Teo Broman; Chelsea Hope; Funita Phan; Shigeki Miyamoto; Ioanna Maroulakou; Natalie Callander; Peiman Hematti; Marta Chesi; P Leif Bergsagel; Paul Sondel; Fotis Asimakopoulos
Journal:  Cancer Immunol Res       Date:  2015-05-04       Impact factor: 11.151

Review 2.  Macrophages in multiple myeloma: emerging concepts and therapeutic implications.

Authors:  Fotis Asimakopoulos; Jaehyup Kim; Ryan A Denu; Chelsea Hope; Jeffrey L Jensen; Samuel J Ollar; Ellen Hebron; Claire Flanagan; Natalie Callander; Peiman Hematti
Journal:  Leuk Lymphoma       Date:  2013-04-11

3.  Tumor progression locus 2 (Tpl2) kinase promotes chemokine receptor expression and macrophage migration during acute inflammation.

Authors:  Sean M Rowley; Teneema Kuriakose; Lee M Dockery; Thi Tran-Nguyen; Aaron D Gingerich; Lai Wei; Wendy T Watford
Journal:  J Biol Chem       Date:  2014-04-08       Impact factor: 5.157

4.  Tpl2 promotes neutrophil trafficking, oxidative burst, and bacterial killing.

Authors:  Nicole V Acuff; Xin Li; Jessica Elmore; Balázs Rada; Wendy T Watford
Journal:  J Leukoc Biol       Date:  2017-03-29       Impact factor: 4.962

5.  MAP3K8 kinase regulates myeloma growth by cell-autonomous and non-autonomous mechanisms involving myeloma-associated monocytes/macrophages.

Authors:  Ellen Hebron; Chelsea Hope; Jaehyup Kim; Jeffrey L Jensen; Claire Flanagan; Neehar Bhatia; Ioanna Maroulakou; Constantine Mitsiades; Shigeki Miyamoto; Natalie Callander; Peiman Hematti; Fotis Asimakopoulos
Journal:  Br J Haematol       Date:  2012-12-18       Impact factor: 6.998

6.  The HIF-1 transcription complex is essential for translational control of myeloid hematopoietic cell function by maintaining mTOR phosphorylation.

Authors:  Inna M Yasinska; Bernhard F Gibbs; Gurprit S Lall; Vadim V Sumbayev
Journal:  Cell Mol Life Sci       Date:  2013-07-20       Impact factor: 9.261

7.  TPL2 kinase regulates the inflammatory milieu of the myeloma niche.

Authors:  Chelsea Hope; Samuel J Ollar; Erika Heninger; Ellen Hebron; Jeffrey L Jensen; Jaehyup Kim; Ioanna Maroulakou; Shigeki Miyamoto; Catherine Leith; David T Yang; Natalie Callander; Peiman Hematti; Marta Chesi; P Leif Bergsagel; Fotis Asimakopoulos
Journal:  Blood       Date:  2014-04-10       Impact factor: 22.113

8.  Tumor Progression Locus 2 (Tpl2) Activates the Mammalian Target of Rapamycin (mTOR) Pathway, Inhibits Forkhead Box P3 (FoxP3) Expression, and Limits Regulatory T Cell (Treg) Immunosuppressive Functions.

Authors:  Xin Li; Nicole V Acuff; Angela R Peeks; Rebecca Kirkland; Kara D Wyatt; Tamas Nagy; Wendy T Watford
Journal:  J Biol Chem       Date:  2016-06-03       Impact factor: 5.157

9.  Cot/tpl2 participates in the activation of macrophages by adiponectin.

Authors:  Carlos Sanz-Garcia; Laura E Nagy; Miguel A Lasunción; Margarita Fernandez; Susana Alemany
Journal:  J Leukoc Biol       Date:  2014-02-14       Impact factor: 4.962

10.  Sterile inflammation in acetaminophen-induced liver injury is mediated by Cot/tpl2.

Authors:  Carlos Sanz-Garcia; Gemma Ferrer-Mayorga; Águeda González-Rodríguez; Angela M Valverde; Antonio Martín-Duce; Juan P Velasco-Martín; Javier Regadera; Margarita Fernández; Susana Alemany
Journal:  J Biol Chem       Date:  2013-04-09       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.